Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/17486
ชื่อเรื่อง: Rituximab therapy for treatment of pemphigus in Southeast Asians
ผู้แต่ง: Kanokrungsee S.
Anuntrangsee T.
Tankunakorn J.
Srisuwanwattana P.
Suchonwanit P.
Chanprapaph K.
Keywords: desmoglein 1 antibody
rituximab
rituximab
adult
aging
Article
cohort analysis
disease duration
drug efficacy
drug safety
early intervention
female
human
major clinical study
male
middle aged
multiple cycle treatment
pemphigus
predictive value
prognosis
recurrent disease
remission
retrospective study
Southeast Asian
Thai (citizen)
treatment outcome
adolescent
aged
Asian continental ancestry group
pemphigus
young adult
Adolescent
Adult
Aged
Asian Continental Ancestry Group
Cohort Studies
Female
Humans
Male
Middle Aged
Pemphigus
Retrospective Studies
Rituximab
Young Adult
วันที่เผยแพร่: 2021
บทคัดย่อ: Background: Rituximab provides more effective and less adverse effects than the standard dose of corticosteroids, but evidence on its efficacy and safety in the Thai population is lacking. Objective: To evaluate the efficacy and safety of rituximab in the treatment of pemphigus and also to determine prognostic factors linked to the treatment outcomes. Methods: Pemphigus patients who received rituximab from November 2017 to December 2020 were retrospectively reviewed. The outcome was evaluated by using early (end of consolidation phase [ECP]) and late endpoints (complete remission [CR] on/off therapy, immunological remission [IR], and relapse). Adverse events were noted. Prognostic factors associated with remission and relapse were analyzed. Results: Of 53 pemphigus patients, all attained ECP within 1.61 months. Almost 80% achieved CR on therapy within a median time of 6.36 months, while 33.9% reached CR off therapy in 19.74 months. Nearly half had IR within a median time of 6.88 months. Relapse occurred in 33.3% with a median time of 14 months. In multivariate analysis, receiving rituximab within 12 months of disease duration was more likely to achieve CR off therapy and IR (hazard ratio [HR] 3.79; 95% confidence interval [CI] 1.38, 10.42; P = 0.01 and HR 2.74; 95% CI 1.12, 6.69; P = 0.027, respectively), whereas older patients and positive anti-desmoglein 1 levels at the time of CR were predictive indicators for relapse (HR 1.07; 95% CI 1.01, 1.13; P = 0.036 and HR 4.38; 95% CI 1.24, 15.46; P = 0.022, respectively). The treatment-related adverse effects occurred in 33.9%. Conclusion: Rituximab is effective and safe in Thai pemphigus patients. Early administration of rituximab was a predictor of clinical and immunological remission. Older age and persistently positive anti-Dsg1 were correlated with disease relapse. © 2021 Kanokrungsee et al.
URI: https://ir.swu.ac.th/jspui/handle/123456789/17486
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105024589&doi=10.2147%2fDDDT.S306046&partnerID=40&md5=ce2438b86504248d0fe663b282458ede
ISSN: 11778881
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.